Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol

Barnes, Theresa; Moots, Robert J.

doi:10.2147/nano.2007.2.1.3

Cited by 41 publications

(44 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two new TNF inhibitors, golimumab (a fully human anti-TNF␣ monoclonal antibody) and certolizumab pegol (a PEGylated FabЈ fragment of a humanized anti-TNF monoclonal antibody), have more recently been shown to be effective in the treatment of RA (83)(84)(85)(86)(87)(88). Thus, TNF␣ has clearly been proven to be a good target for RA treatment and has fulfilled the expectations raised during the preclinical studies performed in animal models.…”

Section: From Animal Models Toward the Clinicmentioning

confidence: 99%

Evaluation of therapeutic targets in animal models of arthritis: How does it relate to rheumatoid arthritis?

Bevaart¹,

Vervoordeldonk²,

Tak³

2010

Arthritis & Rheumatism

228

193

View full text Add to dashboard Cite

There are accumulating data describing the association between diabetes and cancer mortality from Westernised populations. There are no data describing the relationship between diabetes and cancer mortality in African or South Asian populations from developing countries. We explored the relationship of abnormal glucose tolerance and diabetes on cancer mortality risk in a large, multi‐ethnic cohort from the developing nation of Mauritius. Population‐based surveys were undertaken in 1987, 1992 and 1998. The 9559 participants comprised 66% of South Asian (Indian), 27% of African (Creole), and 7% of Chinese descent. Cox's proportional hazards model with time varying covariates was used to obtain hazard ratios (HRs) and 95% confidence intervals (95% CI) for risk of cancer mortality, after adjustment for confounding factors. In men, but not women, cancer mortality risk increased with rising 2h‐PG levels with HR for the top versus bottom quintile of 2.77 (95%CI: 1.28 to 5.98). South Asian men with known diabetes had a significantly greater risk of cancer mortality than those with normal glucose tolerance (NGT) HR: 2.74 (95%CI: 1.00‐7.56). Overall, impaired glucose tolerance was associated with an elevated risk of cancer mortality compared to NGT (HR: 1.47, 95% CI: 0.98–2.19), though this was not significant. We have shown that the association between abnormal glucose tolerance and cancer extends to those of African and South Asian descent. These results highlight the importance of understanding this relationship in a global context to direct future health policy given the rapid increase in type 2 diabetes, especially in developing nations.

show abstract

Section: From Animal Models Toward the Clinicmentioning

confidence: 99%

Evaluation of therapeutic targets in animal models of arthritis: How does it relate to rheumatoid arthritis?

Bevaart¹,

Vervoordeldonk²,

Tak³

2010

Arthritis & Rheumatism

228

193

View full text Add to dashboard Cite

show abstract

“…The primary end-points were met in the two BLISS (-52 and -76) trials 39 . Furthermore, several new Anti-TNF agents including certolizumab (CDP-870) 40 are in the pipeline. Other agents undergoing trials are denosumab 41 , Anti IL-17, latrunculin A 42 and drugs targeting the toll like receptors (MD-2, CD-36).…”

Section: Biologics Used For Other Indicationsmentioning

confidence: 99%

Biologics: a new weapon in the war against autoimmune joint disease

Wijesinghe

Seneviratne

Galappatthy

et al. 2011

J of Cey Coll of Phy

View full text Add to dashboard Cite

“…‹nsanda-ki yar› ömrü 13 gün olup, ayda bir cilt-alt› enjeksiyon fleklinde uygulanabilmektedir. 54 Ajan›n yap›s›nda di¤er ajanlarda oldu¤u gibi Fc bölgesi olmad›¤› için, bu ajan›n vitro kompleman aktivasyonu, antikora ba¤›ml› hücresel sitotoksisite veya apoptosis indüklememektedir. [54][55][56] Ajan›n basitlefltirilmifl yap›s›n›n bir di¤er avantaj›da üre-timinde E.Coli gibi bir bakteri kullan›larak çok daha ucuza mal edilebilmesidir.…”

Section: Tnf Antagonistleriunclassified

“…54 Ajan›n yap›s›nda di¤er ajanlarda oldu¤u gibi Fc bölgesi olmad›¤› için, bu ajan›n vitro kompleman aktivasyonu, antikora ba¤›ml› hücresel sitotoksisite veya apoptosis indüklememektedir. [54][55][56] Ajan›n basitlefltirilmifl yap›s›n›n bir di¤er avantaj›da üre-timinde E.Coli gibi bir bakteri kullan›larak çok daha ucuza mal edilebilmesidir. 54 Literatürde bu ajan en çok Crohn hastal›¤› ve RA üzerinde araflt›r›lm›flt›r ve her iki tabloda da etkili oldu¤unu bildiren yay›nlar mevcuttur.…”

Section: Tnf Antagonistleriunclassified

See 1 more Smart Citation

New Treatment Alternatives in the Management of Non-İnfectious İntraocular İnflammations: Biologic Agents

Emre¹,

Tutkun²

2011

tjo

View full text Add to dashboard Cite

ÖzetEnfeksiyöz olmayan üveitlerin tedavisinde son y›llara kadar genel olarak immün sistemi bask›layan ilaçlar kullan›lmak-tayd›. Ancak gen mühendisli¤indeki geliflmeler, inflamatuar süreçte yer alan özgün molekülleri hedefleyen proteinlerin sentezini ve bu proteinlerin terapötik olarak kullan›lmalar›n› mümkün k›lm›flt›r. Genel olarak protein yap›s›ndaki bu ajanlar biyolojik ajanlar olarak adland›r›lm›fllard›r. Oftalmologlar›n biyolojik ajanlar ile tecrübeleri s›n›rl› olsa da, bu ajanlar romatoloji ve dermatoloji baflta olmak üzere di¤er disiplinler taraf›ndan yo¤un biçimde kullan›lmaktad›rlar. ‹nterferon, infliksimab ve adalimumab baflta olmak üzere birçok biyolojik ajan›n üveit hastalar›nda kullan›m› ile ilgili literatür verisi olmas›na ra¤men henüz bu endikasyonda ruhsatl› kullan›mlar› yoktur. Ayr›ca bu ajanlar›n kullan›m› s›ras›nda dikkat edilmesi gereken güvenlik önlemleri ve önemli risk faktörleri mevcuttur. Bu derlemenin amac›, dirençli üveit hastalar›nda kullan›labilen biyolojik ajanlar konusunda güncel ve kapsaml› bilgi sunmakt›r. ( SummaryConventional immunosuppressive agents have been traditionally used for the treatment of noninfectious uveitis. Recent developments in genetic engineering have made it possible to synthesize proteins that target specific molecules playing role in the inflammatory response. These agents are generally in protein structure and are named biologic agents. While there is limited experience with biologics in the field of ophthalmology, they are commonly used in other disciplines such as rheumatology and dermatology. Although considerable data have accumulated in the uveitis literature regarding the use of biologic agents, including mainly interferon, infliximab, and adalimumab, their use for this indication is still off-label. Moreover, there are certain precautions that have to be taken into account, as well as important safety issues associated with their use. The purpose of this paper is to present an updated comprehensive review of biologic agents that may be used for the treatment of refractory uveitis. (Turk J Ophthalmol 2011; 41: 243-55 GiriflEnfeksiyöz olmayan üveitlerin tedavisinde kullan›lmakta olan immunsupresan ajanlar, ba¤›fl›kl›k sistemini genel olarak bask›lamakta veya sapt›rmaktad›rlar. Bu tedavi yöntem-lerinin sebep olduklar› ciddi yan etkiler ile tedaviye dirençli olgular, hekimleri yeni tedavi aray›fllar›na itmektedir. Son y›llarda araflt›r›lan biyolojik ajanlar, inflamatuar süreçteki öz-gün molekülleri (proteinleri) etkileyerek ba¤›fl›kl›k sisteminde daha s›n›rl› ancak etkin bir tedavi sa¤lamaktad›rlar. Biyolojik ajanlar, moleküler rekombinant DNA teknolojisi kullan›larak elde edilen proteinlerdir. Bu ajanlar›n büyük ço¤un-lu¤u monoklonal antikorlard›r. fiu an için enfeksiyöz olmayan üveitlerin tedavisinde bafll›ca kullan›lan biyolojik ajanlar 3 grupta s›n›fland›r›labilir; i. Interferon-α, ii. TNF-α antagonistleri ve iii. Çeflitli sitokin veya yüzey membran proteini gibi farkl› hedeflere yönelik antikorlar veya füzyon proteinleri.

show abstract

Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol

Cited by 41 publications

References 9 publications

Evaluation of therapeutic targets in animal models of arthritis: How does it relate to rheumatoid arthritis?

Evaluation of therapeutic targets in animal models of arthritis: How does it relate to rheumatoid arthritis?

Biologics: a new weapon in the war against autoimmune joint disease

New Treatment Alternatives in the Management of Non-İnfectious İntraocular İnflammations: Biologic Agents

Contact Info

Product

Resources

About